On January 12, Shanghai Kaikai Industry Company Limited(600272) again issued a notice on stock price fluctuation and stock trading risk. For the recent market rumors about the national confidential formula of Liushen Pill of Shanghai leiyunshang pharmaceutical West Co., Ltd., a wholly-owned subsidiary of the company, it was clarified to the market again: the company does not have any national confidential pharmaceutical formula or Liushen Pill production business; At the same time, it said that most of the company’s performance increase came from non operating profits and losses and was not sustainable.
On January 12, Shanghai Kaikai Industry Company Limited(600272) opened the trading limit, with the share price of 15.98 yuan / share, an increase of 9.98%, and the latest market value of 3.883 billion yuan
(source:)
hot money speculation in the secondary market
Shanghai Kaikai Industry Company Limited(600272) I was also helpless. The clarification announcement was issued again and again, but I still couldn’t stop the enthusiasm of investors, and the share price ushered in the limit again.
According to the reporter’s statistics, in the eight trading days from December 31, 2021 to January 12 this year, Shanghai Kaikai Industry Company Limited(600272) closed eight boards in a row. Compared with 6.65 yuan / share in November 2021, its share price has now risen to 15.98 yuan / share. According to China stock market news, during the continuous trading period, its share price rose 114.21% and the cumulative turnover rate reached 107.23%
(source:)
After hours on January 12, in terms of capital flow, the main inflow was 286 million yuan, the main outflow was 100 million yuan, and the net inflow of main capital in recent 5 days was 722 million yuan. Five business departments of Huatai headquarters, Jiangning Road, Putuo District, Shanghai, Guojun Kunming Renmin Middle Road, Guojun Chongqing Xinnan road and Yinhe Guangzhou Yuejiang middle road bought a total of 59.9962 million yuan.
who is the real owner of the “six God pill”?
It is reported that the successive limit of Shanghai Kaikai Industry Company Limited(600272) share price is closely related to the recent market rumors that its wholly-owned subsidiary Shanghai leiyunshang pharmaceutical West Co., Ltd. has the national confidential formula of Liushen Pill.
On December 24, 2021, an investor asked kaikaishi subsidiary leiyunshang pharmaceutical whether to produce Liushen pills. In response, Shanghai Kaikai Industry Company Limited(600272) said that Liushen pills are not products produced by the pharmaceutical sector of the company, but Liushen pills are sold in all exclusive stores and network platforms of leiyunshang pharmaceutical, At the same time, it does not have the national confidential medical formula of the mentioned “Liushen Pill”.
Later, on December 27, 2021, some investors asked again, Shanghai Kaikai Industry Company Limited(600272) is there any production of confidential formula and Liushen pills? Kaikai pharmaceutical denied it, issued an announcement to clarify it, and said that there may be irrational speculation risk. However, the enthusiasm of the secondary market remains unchanged. What is the relationship between Shanghai Kaikai Industry Company Limited(600272) which once staged “Earth Sky board” and Lei yunshang?
According to tianyancha data, Shanghai Kaikai Industry Company Limited(600272) ‘s leiyunshang is fully known as Shanghai leiyunshang pharmaceutical West Co., Ltd. (hereinafter referred to as “leiyunshang West”), and its ultimate beneficiary is Shanghai Jing\’an District SASAC. However, the pharmacies under leiyunshang in Shanghai are not all pharmacies under Shanghai Kaikai Industry Company Limited(600272) . There is also a pharmacy called Shanghai leiyunshang North District Drug Retail Co., Ltd. (hereinafter referred to as “Shanghai leiyunshang North District”). According to tianyancha data, the largest shareholder of the company is Shanghai leiyunshang Pharmaceutical Co., Ltd. (hereinafter referred to as “Shanghai leiyunshang”), which is mainly a grandson of Shanghai Pharmaceuticals Holding Co.Ltd(601607) .
In addition, the reporter found on the official website of Shanghai leiyunshang Pharmaceutical Co., Ltd. that Shanghai leiyunshang Pharmaceutical Co., Ltd. has the production technology of Liushen Pill, a national intangible cultural heritage project. Its brand originates from “leiyunshang” with a history of nearly 300 years, and its brand name is “Leishi” rather than “leiyunshang”
(source: screenshot of the official website of Shanghai leiyunshang Pharmaceutical Co., Ltd.)
Then who really holds the real secret recipe of “Liushen Pill”? According to the report of global tiger exchange, the enterprise that really obtained the secret recipe is leiyunshang Pharmaceutical Group Co., Ltd. according to the list of protection units of representative projects of national intangible cultural heritage released in 2019, it has the qualification of protection unit of “traditional Chinese medicine preparation method (Liushen Pill making technology of leiyunshang)”.
So what is the origin between the three? It is reported that there are three companies named “leiyunshang” on the market. Although they are not related to each other, the capital behind the three “leiyunshang” is very strong.
Specifically, according to tianyancha data, the ultimate beneficiary of Shanghai Kaikai Industry Company Limited(600272) leiyunshang west district is Shanghai Jing\’an SASAC; The capital of leiyunshang north station is Shanghai Pharmaceuticals Holding Co.Ltd(601607) group; Liushen Pill, named after leiyunshang, is the product of Suzhou leiyunshang National Pharmaceutical Chain Store Co., Ltd., a wholly-owned subsidiary of leiyunshang pharmaceutical. Behind this “root Zhengmiao Hong” leiyunshang, there are not only China Yuanda Group, but also Suzhou SASAC.
transformation “difficult”
Shanghai Kaikai Industry Company Limited(600272) (hereinafter referred to as ” Shanghai Kaikai Industry Company Limited(600272) “) is mainly engaged in the circulation of traditional Chinese medicine, traditional Chinese medicine service (TCM consultation service) and garment production and sales. Among them, the pharmaceutical industry is mainly the wholesale and retail of Chinese and Western patent medicines, the traditional Chinese medicine service with the Chinese time-honored brand “leiyunshang” as the brand, and the sales of high-grade tonics of the independent brand “shanglei”; The garment industry is mainly engaged in the production, wholesale and retail of Chinese time-honored “Kaikai” brand clothing.
Over the past decade, Shanghai Kaikai Industry Company Limited(600272) has been showing a state of increasing income without increasing profit. According to the data, from 2018 to 2020, its revenue was 878 million yuan, 870 million yuan and 762 million yuan respectively, but its net profit was only 35.1421 million yuan, 21.6752 million yuan and 12.9059 million yuan respectively. By the third quarter of 2021, its revenue was 151 million yuan, a year-on-year decrease of 21.97%, and its net profit was only 1.204 million yuan, a year-on-year decrease of 23.06%.
In the first three quarters of 2021, the revenue of Shanghai Kaikai Industry Company Limited(600272) pharmaceutical sector reached 429 million yuan and that of clothing sector reached 31.4502 million yuan. However, the operating revenue of pharmaceutical wholesale and pharmaceutical retail sectors, which account for a large proportion of the pharmaceutical sector, decreased by 29.22% and 11.33% respectively year-on-year.
At the same time, under the double blow of the loss of foreign trade orders and the epidemic, the business of the clothing sector shrank significantly, and the operating revenue and profitability were severely damaged. At present, there are still 27 self operated retail stores under Shanghai Kaikai Industry Company Limited(600272) .
On January 5, 2022, Shanghai Kaikai Industry Company Limited(600272) announced the annual performance forecast for 2021. It is estimated that the annual net profit in 2021 will be between RMB 1.82 million and RMB 22.56 million, with a year-on-year increase of 45% to 65% and earnings per share of RMB 0.08-0.09 per share; The net profit after deduction is expected to be only 3.35 million yuan to 5 million yuan, and the earnings per share after deduction is only 0.01-0.02 yuan / share.
Although the performance is increased in advance, but Shanghai Kaikai Industry Company Limited(600272) also admitted that most of the performance increase comes from non operating profits and losses, rather than the main business. During the reporting period, Shanghai Kaikai Industry Company Limited(600272) received 12.9 million yuan of government subsidies allocated by superior government departments transferred by the company’s controlling shareholder Shanghai Kaikai (Group) Co., Ltd., which were mainly used to cover the expenses of comprehensive reform costs, and said that the income was not sustainable and only had an impact on the current net profit.
In recent years, Shanghai Kaikai Industry Company Limited(600272) has started to march into the field of “great health” in order to implement the transformation. On September 7, 2021, leiyunshang West District, a wholly-owned subsidiary of Shanghai Kaikai Industry Company Limited(600272) , planned to purchase two properties located in Wuding Road and JIANGCHANG West Road, Jing\’an District, Shanghai from Kaikai group, the controlling shareholder of the company. The estimated prices of the asset appraisal institutions were 140 million yuan and 110 million yuan respectively. Its main purpose is to comprehensively promote the “great health strategy” and implement the three-wheel drive development strategy of medicine, medical treatment and medical care.
Although various investments are carried out in an orderly manner, Shanghai Kaikai Industry Company Limited(600272) also said that the initial investment of the newly established self operated medical institution is large, the general investment payback period is 3-5 years, and the depreciation cost, decoration and other expenses will have a certain negative impact on the company’s profits in the early stage of operation.
